Climb Bio released Phase 1 data for CLYM116, showing a ~29-day half-life and strong APRIL suppression that supports every-12-week dosing. The NAVIGATE-2 Phase 2 design targets IgA nephropathy with an 800 mg loading dose followed by 400 mg maintenance, plus autoinjector development for registrational testing. Key catalysts lie in 2026–2027 NAVIGATE-2 readouts and the potential Phase 3 launch in 2027, which could shift the valuation trajectory.
Climb Bio reported favorable Phase 1b budoprutug data in ITP with strong B-cell depletion and meaningful platelet gains, including rituximab-exposed patients. Investors await late-summer PK/PD data for CLYM116 and Q4 readouts in membranous nephropathy and SLE, which could propel further upside if results meet expectations and support the broader BAFF/APRIL inhibitor narrative.
